Search

Displaying results 6541 - 6550 of 10000 in total
  1. Drug

    Cediranib

    go.drugbank.com/drugs/DB04849
    Investigational

    It is being developed clinically as a once-daily oral therapy for the treatment of cancer. … The novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> &lt; 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro.

  2. Drug

    Ketanserin

    go.drugbank.com/drugs/DB12465
    Investigational

    Ketanserin has been investigated for the treatment of Septic Shock, Severe Sepsis, and Diabetic Foot Ulcer.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Vabametkib

    go.drugbank.com/drugs/DB21629
    Investigational

    Vabametkib has a monoisotopic molecular weight of 566.3 Da. … Vabametkib is under investigation in clinical trial NCT05541822 (To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET

  4. Drug

    CRx-401

    go.drugbank.com/drugs/DB05775
    Experimental

    In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and lipid profiles, and this dose … It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent.

  5. Drug

    Azimilide

    go.drugbank.com/drugs/DB04957
    Investigational

    Azimilide is an investigational class III anti-arrhythmic drug that blocks fast and slow components of the delayed rectifier cardiac potassium channels. … It is not approved for use in any country, but is currently in clinical trials in the United States.

  6. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks … Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.

  7. Drug

    Certociclib

    go.drugbank.com/drugs/DB21736
    Investigational

    Certociclib is under investigation in clinical trial NCT05252416 ((VELA) Study of BLU-222 in Advanced Solid Tumors). Certociclib has a monoisotopic molecular weight of 365.14 Da.

  8. Drug

    Fuzapladib

    go.drugbank.com/drugs/DB19478
    Experimental

    The usage of the INN stem '-pladib' in the name indicates that Fuzapladib is a phospholipase A2​ inhibitor. Fuzapladib has a monoisotopic molecular weight of 379.12 Da.

  9. Drug

    Umibecestat

    go.drugbank.com/drugs/DB19898
    Experimental

    The usage of the INN stem '-becestat' in the name indicates that Umibecestat is a beta secretase inhibitor. Umibecestat has a monoisotopic molecular weight of 513.08 Da.

  10. Drug

    Tomicorat

    go.drugbank.com/drugs/DB20822
    Experimental

    The usage of the INN stem '-corat' in the name indicates that Tomicorat is a glucocorticoid receptor agonist. Tomicorat has a monoisotopic molecular weight of 527.21 Da.